Detection of Hairy Cell Leukemia Minimal Residual Disease: Detection by Flow Cytometry
OBJECTIVES: I. Compare the sensitivity of flow cytometry, immunohistochemistry, and
polymerase chain reaction in detecting minimal residual disease following therapy with
cladribine in patients with hairy cell leukemia.
OUTLINE: Blood and bone marrow samples are obtained from patients at time of bone marrow
biopsies to assess minimal residual disease using flow cytometry, immunohistochemistry, and
polymerase chain reaction. Patients are followed for 2 years or until disease relapse.
PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study over 12-24 months.
Observational Model: Cohort, Time Perspective: Prospective
Loann C. Peterson, MD
Robert H. Lurie Cancer Center
United States: Federal Government
|Robert H. Lurie Comprehensive Cancer Center, Northwestern University||Chicago, Illinois 60611|